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1.  Introduction 
1.1 Background of 21-hydroxylase deficiency  
Congenital adrenal hyperplasia (CAH) represents an autosomal recessive disorder 
characterized by a complex imbalance of adrenal steroids (Reisch, Arlt, & Krone, 
2011). The deficiency of any adrenal enzyme required for glucocorticoid (GC) 
synthesis may lead to CAH. When glucocorticoid synthesis is impaired, ACTH is 
chronically elevated through the negative feedback system. This leads to 
overstimulation of the adrenal cortex and consequent hyperplasia of the adrenal gland 
and oversecretion of the steroid precursors. Depending on the location of the 
enzymatic block, there are many types of CAH including 11β-hydroxylase deficiency, 
17α-hydroxylase deficiency, 21-hydroxylase deficiency (21-OHD), 3β-hydroxysteroid 
dehydrogenase deficiency, congenital lipoid adrenal hyperplasia, P450 oxidoreductase 
deficiency, etc. The most common form, 21-OHD due to mutations in the gene 
CYP21A2, is of particular interest since it accounts for more than 90% of all cases of 
CAH (Merke & Bornstein, 2005; Reisch et al., 2013). The mutations result in 
decreased glucocorticoid secretion with or without mineralocorticoid deficiency and 
excess androgens. Newborn screening programmes in most Western countries 
indicate that the incidence of the classical form of 21-OHD is one in 13,000 to 15,000 
live births (Merke & Bornstein, 2005). 
1.1.1 Biochemistry of steroid synthesis 
The precursor of all steroid hormones is cholesterol. It is absorbed from the intestine 
and delivered to the adrenals by low-density lipoproteins (LDL) in the circulation 
(Figure 1). The rate-limiting step in steroidogenesis is the transport of cholesterol 
from cellular store to the inner mitochondrial membrane (Yaffe & Aranda, 2010). 
This transport is mainly governed by the steroidogenic acute regulatory (StAR) 
protein (Stocco & Clark, 1996). The first step of steroidogenesis is conversion of 
cholesterol to pregnenolone. This step is catalyzed by a mitochondral enzyme called 
side-chain cleavage cytochrome P450 (P450scc). Pregnenolone is transported back 
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into the cytosol and then enters the endoplasmic reticulum (ER) to feed the main 
steroid biosynthesis in the adrenal cortex including cortisol, aldosterone and 
dehydroepiandrosterone (DHEA).  
The zona glomerulosa mainly contributes to the production of mineralocorticoids with 
the end product of aldosterone.  
Glucocorticoids are mainly produced in zona fasciculata. In 21-OHD, the enzymatic 
block leads to accumulation of 17-hydroxyprogesterone (17-OHP) and a lack of 
cortisol.   
In the zona glomerulosa, 17-hydroxyprenenolone is converted to DHEA by 
17α-hydroxylase (CYP17A1) after conversion from pregnenolone (Rainey, Carr, 
Sasano, Suzuki, & Mason, 2002). The conversion from DHEA androstenedione is 
further catalyzed by 3β-HSD and then androstenedione can be transported in the 
circulation and metabolized to testosterone and dihydrotestosterone (DHT) in 
extra-adrenal tissue (W. L. Miller, 2009).  
Mutations in CYP21A2 can cause decreased production of aldosterone and cortisol 
combined with an excessive accumulation of precursors (Merke & Bornstein, 2005). 
At the same time, since androgen synthesis is not disrupted, precursors are shunted 





Figure 1 Steroid hormone biosynthesis. The pathways for the synthesis of mineralocoticoids, glucocorticoids and androgens are arranged from 
left to right. The planar structures of the common precursor cholesterol and steroid hormone products are placed near the corresponding labels. 
Enzymes that catalyse each bioconversion are marked in boxes. StAR, steroidogenic acute regulatory protein; P450scc, side-chain cleavage 
cytochrome P450; 3β-HSD, 3β-hydroxysteroid dehydrogenase; CYP21A2, 21-hydroxylase; CYP11B2, aldosterone synthase; CYP17A1, 
17α-hydroxylase; CYP11B1, 11β-hydroxylase; 17β-HSD, 17β-hydroxysteroid dehydrogenase; SRD5A2, steroid-5α reductase type 2; DHEA, 
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1.1.2 Molecular genetics of CYP21A2 
Steroid 21-hydroxylase is encoded by a microsomal cytochrome P450 named 
CYP21A2. It is located in the human leukocyte antigen (HLA) major 
histocompatibility complex (MHC) locus on the short arm of chromosome 6 (6p21.3) 
with the homologous inactive pseudogene, CYP21A1P (CYP21P) (Anna Wedell, 
2011). CYP21A2 and the pseudogene are 3.3kb and have 10 exons with 98% 
homology of nucleotide sequences and 9 introns with 95% homology (Higashi, 
Yoshioka, Yamane, Gotoh, & Fujii-Kuriyama, 1986; White, New, & Dupont, 1986). 
They are close to and alternating with the genes encoding the fourth component of 
serum complement named factor C4B and C4A (Carroll, Campbell, & Porter, 1985; 
White et al., 1985). C4/CYP21 with RP and tenascin X (TNX) comprises a genetic unit 
called RP-C4-CYP21-TNX (RCCX) module. The most common form of RCCX is 
bimodular (Figure 2) (Blanchong et al., 2000). 
Due to the similarity and the proximity of CYP21A2 and CYP21A1P and tandem 
repeats of RCCX region, misalignment may occur during meiosis followed by 
reciprocal recombination (also called unequal crossing over). Furthermore, small or 
large sequences may be transferred or inserted into genes or deleted during apparent 
gene conversion (Koppens, Hoogenboezem, & Degenhart, 2002). Approximately 
65-70% gene conversions are point mutations (Z. Xu, Chen, Merke, & McDonnell, 
2013). Around 95% of all mutations in CYP21A2 causing 21-OHD occur because of 
the reasons stated above with remaining 5% of the mutations arising spontaneously 
without the involvement of the pseudogene in single families (A Wedell, Thilén, 




Figure 2 A schematic map of the HLA major histocompatibility complex on chromosome 6p21.3 containing a bimodular RCCX. HLA-B is 
the nearest HLA Class I gene to CYP21A2, and HLA-DR is the nearest HLA Class II gene. The region in between is termed HLA Class III, 
where the RCCX module is located. Both the pseudogene and the functioning CYP21A2 gene are located in the RCCX module. HLA, human 
leukocyte antigen; RCCX, RP-C4-CYP21-TNX; TNF, tumor necrosis factor; TNXA, tenascin XA; TNXB, tenascin XB. The figure is adapted from 




1.1.3 Clinical manifestations and treatment of 21-OHD 
Decreased production of aldosterone and cortisol, combined with excessive 
production of androgens, leads to the clinical manifestations of 21-OHD. Due to the 
disease severity of 21-OHD, three phenotypes are recognized: salt-wasting 
(SW)21-OHD, simple virilizing (SV) 21-OHD and non-classic (NC)21-OHD. SW and 
SV are also known as classic 21-OHD.  
Since lacking of 21-hydroxylase activity almost completely, SW 21-OHD is the most 
severe form of 21-OHD and accounts for 70% of classic 21-OHD (Pang, 2003). 
Newborns show a life-threatening salt loss together with prenatal virilization of 
external genitalia in affected females. On the contrary, SV 21-OHD patients do not 
have aldosterone deficits and are able to maintain electrolyte balance except during 
infections, trauma etc. Other symptoms like genital virilization in female newborns, 
accelerated growth and precocious puberty during early childhood are similar as the 
SW phenotype (Hargitai et al., 2001). The mildest form, NC 21-OHD is mainly 
diagnosed at a later age. Symptoms of hyperandrogenism like hirsutism, 
oligomenorrhea, acne and infertility show up during childhood and even adulthood. 
The majority of male NC 21-OHD patients are only diagnosed during family 
screening (Maria I New, 2006). 
The aim of 21-OHD treatment is to prevent excessive production of androgens and 
adrenal crises by replacement of glucocorticoid and mineralocorticoid which are 
produced insufficiently. In addition, the targets also include optimising height, 
gonadal development and fertility. 
Currently, steroid replacement is the main treatment, however, its side effects cannot 
be ignored. The long-term use of slightly supraphysiological glucocorticoid doses will 
bring metabolic and cardiovascular risks, such as obesity, hypertension, type 2 
diabetes and dyslipidemia. Overtreatment with glucocorticoids and mineralocorticoids 
also suppresses growth, especially applying longer-acting glucocorticoids such as 
prednisone during puberty (Bonfig, Bechtold, Schmidt, Knorr, & Schwarz, 2007). 
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Thus, despite over 50 years’ experience with steroid replacement therapy, the 
management of 21-OHD remains difficult and new therapeutic approaches with the 
least risk of side effects are needed.  
1.2 Structural models of CYP21A2 protein  
Previously, different homology models of human CYP21A2 protein structures based 
on other known P450 structures have been constructed (Mornet & Gibrat, 2000; Tiina 
Robins, Carlsson, Sunnerhagen, Wedell, & Persson, 2006). Many structure-based 
studies of the mutants causing 21-OHD have been performed using these models 
(Bleicken et al., 2009; Minutolo et al., 2011; Tardy et al., 2010). However, these 
models such as CYP2C5 and CYP51 proteins only have the sequence homology of 31% 
(Haider et al., 2013). Thus, the regions with low sequence homology could have high 
uncertainties. In addition, the substrate of the model based upon CYP51 protein 
structure was estriol, which led to a different ligand-binding site as that of CYP21A2. 
Overall, using the previous models of CYP21A2 protein would probably influence the 
accuracy of the molecular basis study of 21-OHD. In 2012, Zhao’s group constructed 
a bovine CYP21A2 protein crystal structure complexed with 17OHP, and following 
them Haider’s group extracted structural features from their template, aligned bovine 
and human sequences and derived a 3D structure of the humanized CYP21A2 protein 
(Haider et al., 2013; Zhao et al., 2012). Almost 79% sequence identity is shared 
between bovine and human enzyme and over 85% of known CYP21A2 protein 
variants are identical. Furthermore, almost all structural elements of human CYP21A2 
protein can also be observed in bovine molecular models. Therefore, the model based 
on bovine showed the closed representation of human CYP21A2 protein structures. 
Recently, Pallan and co-workers expressed human CYP21A2 protein in E. coli and 
determined the human CYP21A2 protein crystal structure complexed with the 
substrate progesterone, which providing a better insight into structural and functional 
changes induced by 21-OHD -causing mutations (Pallan, Wang, et al., 2015). 
In general, like other known P450 protein structures, the overall structure of the 
CYP21A2 protein contains 16 α-helices and 9 β-sheet domains (Figure 3). A 
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conserved hydrophobic P450 catalytic active site is well defined around a single heme 
prosthetic group. One 17-OHP/progesterone molecule is situated in the proximal 
portion of the substrate-binding site over the heme. The bovine CYP21A2 protein 
crystal structure showed that besides one 17-OHP binding in the active site, there was 
another 17-OHP located at the substrate entrance, waiting for the dissociation and 
moving into the active site (Haider et al., 2013; Zhao et al., 2012). Approximately 35% 
of the amino acid residues are in close proximity to the heme or substrate-binding 
sites. They are highly conserved and play an important role in maintaining the enzyme 
folding and activity. Therefore, it is easily to comprehend that protein variants 
occurring at these residues in the core of enzyme result often in SW21-OHD, the most 
severe 21-OHD phenotype. Conversely, according to the protein models of CYP21A2, 
SV and NC mutations are more typically positioned at peripheral regions or surface of 
protein. They may disrupt the transmembrane region, conserved hydrophobic patches 
or secondary bonds between residues. Therefore, in terms of active site of amino acid 
and the degree of mutation-induced damages in structural models of CYP21A2 





Figure 3 A humanized model of CYP21A2 protein. 
The protein main chain is shown in ribbon mode 
and rainbow coloring, from N terminus (blue) to C 
terminus (red). Carbon, nitrogen, and oxygen 
atoms of the heme moiety are colored in grey, blue, 
and red, respectively, and Fe3+ is shown as an 
orange sphere. Secondary structure contains 16 
α-helices and 9 β-sheets in rainbow coloring. Nine 




Increasing studies recently found that some amino acids residues have significant 
impact on the protein stability and folding in diseases such as hemochromatosis (de 
Almeida et al., 2007) and nephrogenic diabetes insipidus (Robben, Sze, Knoers, & 
Deen, 2006). As we have shown 9 residues in Figure 3 and Table 1, they form specific 
interactions with other residues from different helices or sheets, or provide right size 
fitting in limited space to maintain the secondary structure and conformational 
flexibility of protein. In this project, we will investigate 13 protein variants which are 
caused by point mutations from 9 residues as depicted in Figure 3. These 13 protein 
variants cover all three phenotypes of 21-OHD (salt-wasting, simple virilising, 
non-classic). All are based on naturally occurring, clinical relevant mutations with 
known and described clinical phenotypes well correlating with the residual enzyme 
activity in vitro. Since these residues are far from the heme and substrate binding site, 
they do not provide the direct disruption of heme and/or substrate binding, ensuring 
that active site is not directly affected. However, some studies found that these protein 
variants could induce the structural instability of CYP21A2 proteins (Haider et al., 
2013; Zhao et al., 2012). Table 1 gives an overview of the selected residues with their 
known clinical phenotype, their localisation in the protein and the structural 
characteristic based on the bovine and human crystal structure of the protein. When 
the instable proteins emerging in the ER, they could be targeted by ER quality control 





Table 1 Proposed structural basis of residues which that have been selected for investigation in this project.  





P30L NC (30%)(Tusie-Luna, Speiser, Dumic, 
New, & White, 1991) 
It is lodged in a hydrophobic cavity constituted by L29, 
I59, V70, I374, Y377 and I379 on the surface of the 
protein, forms a hinge with P31 to help attach the P450 
to the membrane. 
P30Q SW (0%)(Lajic, Nikoshkov, Holst, & Wedell, 
1999) 
G90 B-B' Loop  G90V SW (0%)(Nunez, Lobato, White, & 
Meseguer, 1999) 
It is adjacent to R91, which has a hydrogen bond with 
the propionate side chains of heme. 
I172 E-Helix I172N SV (<2%)(Tusie-Luna, Traktman, & White, 
1990) 
The isoleucine residue is located in a hydrophobic 
pocket, surrounded by M186 and M187 on F-Helix. 
V281 I-Helix V281G SV (3.9%)(Krone, Braun, Roscher, Knorr, & 
Schwarz, 2000) 
V281 forms a hydrophobic patch together with some 
other hydrophobic residues on H-helix. 
V281L NC (20%) (Tusie-Luna et al., 1990) 




Residues Localization Mutations Phenotype (residual enzyme activity in vitro 
progesterone) 
Structural basis 
R356 K-Helix R356Q SV (1.1%)(Lajic et al., 1997) R356 forms a hydrogen bonding with Q389 on K’-helix 
and Q462 on β8-β9 loop. R356W SW (0%)(Chiou, Hu, & Chung, 1990) 
G375 β5 β6 loop G375S SW (<1%)(Lajic et al., 2002) The β5 β6 loop, where G375 is positioned, can only 
suitable for the smallest amino acid residue. 
P453 β8 Sheet P453S NC (20-46%)(Nikoshkov, Lajic, Holst, 
Wedell, & Luthman, 1997; Owerbach, 
Sherman, Ballard, & Azziz, 1992) 
P453 is located in a hydrophobic pocket surrounded by 
L308 (helix I), L452 (β8-sheet), L458 (β8-β9 loop). A 
sharp turn begins from proline and introduces rigidity. 
R483 C-terminal 
loop 
R483Q NC (3.8%)(Stikkelbroeck et al., 2003) There is a salt-bridge formation between R483 and 
D322. R483W SW (0%)(Kharrat et al., 2004) 
Source: Summary from the crystal structural model of human CYP21A2 protein and the humanized model of CYP21A2 protein based on bovine 





1.3 ER quality control (ERQC) 
In eukaryotic cells, after nascent proteins are translated in the cytosol, they will be 
folded and assembled into mature proteins in specific compartments in the cells. 
Nearly one third human genome product is processed in the ER (Kelly & Balch, 
2006). 
As a central processor that controls protein folding and assembly, ER has developed a 
strict quality control system known as ERQC (Figure 4). ERQC is achieved through 
two execution pathways: (i) completely folded and assembled proteins can be 
exported from the ER to the Golgi complex (Lee, Miller, Goldberg, Orci, & 
Schekman, 2004). (ii) terminally unfolded or misfolded proteins are subjected to 
degradation by ERAD process (McCracken & Brodsky, 2005). 
1.3.1 ERQC and ERAD of P450 proteins 
CYP21A2 is a member of the cytochrome P450 family of enzymes. P450 proteins are 
all membrane bound and located in different subcellular compartments. Many of them 
including CYP21A2 protein reside in the membranes of ER. With assist of many 
chaperones and cellular proteins in the ER, proteins including P450 proteins can be 
folded correctly and avoided from targeting to the ERAD pathway (Lambert et al., 
2001). It was found that heat-shock protein70 (HSP 70), HSP 90 and hsp-organizing 
protein (hop) bind to CYP2E1 and help it to stabilize. After the inhibition of HSP 90, 
increased degradation of CYP2E1 was found (Morishima et al., 2005). 
When a P450 protein fails to acquire their native structure, it can be routed for the 
degradation progress known as ERAD (Correia & Liao, 2007). The most crucial step 
is marking P450 proteins by ubiquitylation. Chaperones and cochaperones can bind 
hydrophobic regions of misfolded proteins and help the misfolded proteins to be 
recognized by ubiquitin ligases (E3) (Park et al., 2007). E3 ligases can bridge the 
proteins with ubiquitin-conjugating enzymes (E2) (Zhen Xu et al., 2006). Then E3 
ligases together with E2 transfer ubiquitin to the serine/threonine residues and less 
frequently lysine residues of targeted protein (Shimizu, Okuda-Shimizu, & 
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Hendershot, 2010). A cytoplasmic protein complex containing the AAA-ATPase 
cdc48p (also termed p97 in mammals) plays an important role in protein extraction 
from the membrane into cytosol (Acharya, Liao, Engel, & Correia, 2011; Chapman, 
Fry, & Kang, 2011). In cells containing mutated cdc48p gene, the degradation of 
CYP3A4 was shown to be inhibited (Liao, Faouzi, Karyakin, & Correia, 2006). Then 
the substrates can be transferred to the 26S proteasome for degradation by shuttle 
proteins which can bind to polyubiquitin chains of substrates and the proteasome 
subunits (J. Miller & Gordon, 2005). 
1.3.2 The mechanism that protein-folding problems cause disease 
ERQC is of great importance for maintaining proteins to function appropriately. 
However, when mutations cause misfolded and less functional forms of proteins and 
ERQC cannot control properly, as a result, many diseases could happen. 
Firstly, improper ERAD can cause degradation or aggregation of proteins. ERAD is 
required for preventing the accumulation of misfolded or unfolded proteins. Thus, 
inefficient removal of misfolded proteins results in aggregation and subsequently 
influence the cell function. Similarly, overactive ERAD leading to elimination of 
variant proteins by degradation can also be the cause of development of some diseases. 
Since variant proteins still retain part of function even if they are misfolded, excessive 
elimination leads to loss-of-function. Furthermore, variant proteins that cannot 
achieve the correct folding encounters disturbed trafficking. Mutations in the 
N-terminal signal sequences lead to structural instability of the anchor of P450 
proteins. Therefore, P450 proteins interactions with the ER membrane are disrupted, 





Figure 4 A simplified diagram of the processes involved in protein folding in the ER. The polypeptides are translated from the ribosome 
directly into the ER, where they are folded and assembled into native functional proteins with the help of molecular chaperones and 
cochaperones. Then cytosolic coat protein II (COPII) coat mediates the most of proteins export from the ER to the Golgi complex via the 
secretory pathway, while a small fraction of proteins, including the P450 proteins, are retained in the ER. However, misfolding proteins are 
detected by ERQC and removed from the ER to cytosol through retrotranslocation. Finally, they are ubiquitinated and degraded by proteasomes 
as part of the ERAD system. The figure is adapted from Fig.1 from Ellgaard & Helenius (Ellgaard & Helenius, 2003).
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1.4 Therapeutic approaches in protein folding diseases 
Numerous genetic diseases occur mainly due to protein misfolding. Treating these 
diseases is a great challenge. Some of the therapeutic approaches which have been 
found recently are described below. 
1.4.1 Reduced temperature treatment 
It has been proven that by reducing the incubation temperature for cell growth, the 
variant proteins can be treated. For example, low temperature at 27°C increased the 
ability of ∆F508CFTR to fold and the biochemical and functional expression at the 
cell surface (French et al., 1996; Heda & Marino, 2000). In addition to ∆F508CFTR, 
reduced temperature has been shown that the decreased degradation, the increased 
amount and stability of immature or mature proteins happened in different misfolded 
proteins such as vasopressin type-2 receptor (V2R) (Robben et al., 2006), AAT 
(Burrows, Willis, & Perlmutter, 2000), prion protein (Gu & Singh, 2004). The 
mechanism of reduced temperature treatment may be related with escaping the ER 
quality control system so that proteins can avoid degradation and process fully in the 
ER (Powell & Zeitlin, 2002). Moreover, under low temperature, protein increases its 
relative thermal stability to support themselves to export from ER (Aridor, 2007). 
Although reduced temperature cannot be achieved in mammal’s body, these studies 
have provided a scientific approach that reduced temperature treatment can be 
manipulated in the cells.  
1.4.2 Chemical chaperones 
A number of studies published in recent years showed that a group of small molecular 
compounds can stabilize variant proteins without direct specific binding to the 
proteins. These compounds have been called ‘chemical chaperones’. There are 
different classifications of them including osmolytes or hydrophobic compounds. The 
mechanisms involved are also diverse, including stabilization of misfolded proteins, 
raised production of proteins, decreased aggregation, change of the production or 
activity of endogenous chaperones, and intervention of nonproductive binding 
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interactions with other resident proteins (Perlmutter, 2002). Since the chemical 
chaperones do not bind with proteins specifically, they often have various pathologic 
conditions that they can apply for. Although most studies are conducted in cells, it is 
very theoretically attractive for protein folding diseases treatment. 
4-Phenylbutyric acid (4-PBA) is a low-molecular weight fatty acid that has recently 
been found to be involved in protein folding with the chaperone activity. 4-PBA is 
known as a transcriptional regulator and inhibitor of histone deacetylase (Cuisset, 
Tichonicky, Jaffray, & Delpech, 1997; D'Anna, Tobey, & Gurley, 1980; Klehr, 
Schlake, Maass, & Bode, 1992). The oral form, Buphenyl® is an the U.S. Food and 
Drug Administration (FDA) approved new drug for the chronic management of some 
urea cycle disorders (Maestri, Brusilow, Clissold, & Bassett, 1996) and used in 
clinical trials for thalassemia (Collins et al., 1995) and sickle cell anemia (Resar et al., 
2002). Ruvenstein et al. first studied the chaperone-like activity in IB3-1 cells and 
nasal polyp epithelial cells from cystic fibrosis (CF) patients (R C Rubenstein, Egan, 
& Zeitlin, 1997). They found that the molecular mass of CFTR increased and 
forskolin-activated chloride secretion restored. After that, the chaperone-like activity 
of 4-PBA is continually found in many other diseases including AAT deficiency 
(Burrows et al., 2000), nephrogenic diabetes insipidus (Robben et al., 2006) and 
hereditary hemochromatosis (de Almeida et al., 2007). Moreover, besides the cell 
model experiment, 4-PBA has been tested as a chemical chaperone in the mouse 
model by oral administration and well tolerated by the mice. The result showed an 
raised production of proteins in blood (Burrows et al., 2000). Since 4-PBA has been 
used safely in humans, it is a potential approach to protein folding diseases in the 
future. 
1.5 Hypothesis 
Through CYP21A2 protein molecular structures, impaired protein stability and the 
organization of secondary structures of protein can be the explanations for the severity 
of the 21-OHD clinical manifestations, indicating that 21-OHD may be in part a 
protein folding disease. Thus, in this research, we will investigate 13 protein variants 
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(Table 1) which are caused by point mutations and considered to be related with 
impaired protein stability. We hypothesize that 21-OHD derived from some specific 
mutations affects stability of CYP21A2 protein which can be enhanced through 




2. Aim of the thesis 
1. To investigate protein half-life of naturally occurring, clinically relevant protein 
variants causing 21-OHD and to investigate the correlation between protein 
structure, functional data and clinical phenotype. 
2. To evaluate CYP21A2 protein as a temperature-sensitive protein and reduced 
temperature treatment to enhance the half-life of CYP21A2 variant proteins in 
vitro. 
3. To explore the possibility of using a chemical chaperone to enhance the half-life 




3.  Methods and materials 
3.1 Site-directed mutagenesis and sequencing 
Mutations were introduced into the pcDNA6/V5-His A, B and C mutagenesis vector 
containing pcDNA6/V5-His-CYP21A2, in which the full-length normal human 
CYP21A2 cDNA had been cloned. Site-directed mutagenesis was performed using 
QuickChange site-directed mutagenesis kit. It allows site-specific mutation in 
virtually any double-stranded plasmid. Site-directed mutagenesis has already been 
performed in our lab by this method above and E. coli with mutated plasmid were 
ready to use for my work. Insertion of the mutations and the integrity of the insert 
were checked by direct sequencing. 
3.2 Isolation of vector-DNA 
Over-night transformed E. coli cultures were grown at 37 °C and 200 rpm in LB 
medium containing ampicillin 50 µg/mL. The next day, the cells were harvested by 
centrifugation at 6000 g for 15 minutes. DNA was extracted with PureYield Plasmid 
Midiprep System kit according to its manufacturer’s protocol. The DNA UV 
absorbance was measured using a Nanodrop-ND1000. 
3.3 Cell culture 
In order to study the activity and half-life of CYP21A2 protein variants, COS-7 cells 
were used for transient transfection. COS-7 cell line is derived from African green 
monkey kidney cells (CV-1) through transformation with a origin-defective Simian 
Vacuolating Virus 40 (SV40), which has integrated into COS cell chromosomal DNA 
(Aruffo, 2001). The main reason for using COS-7 cells is the high copy number 
achieved by the replication of the packaging plasmids in COS-7 cells (approximately 
10,000 to 100,000 copies/cell within 48 hours post-transfection) (Aruffo, 2001). 
COS-7 cell line was generated by YakovGluzman (Gluzman, 1981) and obtained 
from PD Dr. Soeren Gersting, Department of Department of Molecular Pediatrics, Dr. 
von Haunersches Kinderspital. COS-7 cells were cultured in RPMI 1640 medium 
supplemented with 10% fetal bovine serum and 1% penicillin / streptomycin. Cells 
were grown in sterile conditions in a humidified atmosphere (37°C and 5 % CO2) in 
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cell culture flasks allowing adherent growth in a monolayer. Cells were passaged 
every second to third day with a seeding ratio of 1:6. Harvesting was achieved by 
trypsinization, and then cells were washed and resuspended in the medium. The 
numbers of passages for cell used in the experiments are between 10 to 20. 
3.4 In vitro expression of CYP21A2 protein variants, reduced temperature and 4-PBA 
treatment in COS-7 cells 
Transfection of pcDNA6/V5-His-CYP21A2WT and mutant constructs was performed 
by using X-tremeGENE HP DNA Transfection Reagent. COS-7 cells were seeded in 
48-well plates with approximately 75, 000 cells per well, and incubated for 24 hours 
at 37 °C. 0.1 μg DNA was transfected into cells transiently using 0.3μl of 
X-tremeGENE HP each well. In a subset of experiments cells were either (i) 
incubated at 30 °C for 48 hours or (ii) treated with 1mM 4-PBA at 37 °C for 24 hours. 
For the 4-PBA treatment, old culture medium was removed and cells were washed 
with DPBS after incubated with transfection reagents for 24h at 37°C. Then 500μl 
diluted 1mM 4-PBA in culture medium from 4-PBA stock solution was added to each 
well. Each subset has control groups treated at 37 °C for 48 hours and with blank 
medium respectively. 
3.5 Protein isolation and concentration determination 
Cells in 48-well plates were harvested for protein and washed twice with DPBS. Then 
cells were lysed by directly adding RIPA buffer supplemented with protease inhibitor 
cocktails on ice for 15 minutes and subsequently shaking at 300 rpm for 30min. Then 
the plates were centrifuged at 4000 rpm for 10 minutes at 4°C and supernatant from 
wells was collected to tubes. Protein concentration was measured using a protein 
assay based on the method of Bradford (Bradford, 1976). Bovine serum albumin 
(BSA) standards between 0 and 2 mg/ml were prepared in the same matrix as protein 
samples. Samples were measured on Multilabel Counter 1420 Victor and the protein 
concentrations were calculated by the reference values from the protein standard. 
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3.6 Limited proteolysis by proteinase K and western blot 
Proteinase K is an endolytic protease that cleaves peptide bonds at the carboxylic 
sides of hydrophobic amino acid residues (aliphatic, aromatic and other hydrophobic 
amino acids). Stability of protein can be investigated by limited proteolysis with 
proteinase K. The proteolytic event is not dictated by the speciﬁcity of the protease K 
but the stereochemistry and ﬂexibility of the protein substrate (Fontana et al., 2004; 
Gersting et al., 2008). 
Wild type proteins (10 μg) and its variant proteins were digested with proteinase K (at 
a ratio of 1:20,000) at 37°C. Proteolysis was terminated at 0.5, 1, 2, 5, 10, 30, 60, and 
120 min time points by addition of the 4 mM (final concentration) protease inhibitor 
phenylmethylsulphonyl fluoride (PMSF). Protein separation was achieved by running 
mixtures on a SDS-PAGE with 4–20 % gradient gels together with PageRuler 
pre-stained protein ladder. Electrophoresis was carried out for 45 minutes with 200 V 
in the Mini-PROTEAN II electrophoresis system filled with 1x running buffer. 
Size-separated protein on gels were then electroblotted to methanol activated 
Hybond-P polyvinylidenedifluoride (PVDF) membrane. The gels were placed in the 
'transfer sandwich' (filter paper-gel-membrane-filter paper) in vertical buffer tank 
under 30 V for 60 minutes. The membranes were blocked in blotting-grade blocking 
solution for 1 hour and then incubated with a Mouse anti-V5 antibody overnight at 
4°C. After TBST washing 3x 10 min with gentle shaking, membranes were incubated 
with HRP conjugated secondary antibodies for 1 hour. Detection was achieved by 
soaking the membranes using the SuperSignal West Femto Maximum Sensitivity 
Substrate kit according to the manufacturer’s protocol. Chemiluminescence was 
monitored and the resulting protein bands were quantified by the ChemiDoc™ XRS+ 
System with Image Lab™ Software. Calculation of half-lives of degradation was 





3.7.1 Laboratory equipment and software 
Item  Model Manufacturer 
Analytics software SPSS 19 IBM 
Autoclave                   VX-75    Systec 
Benchtop centrifuge           5804R     Eppendorf 
Benchtop centrifuge           5810R   Eppendorf 
Biological safety cabinet       Safe 2020 Class II   Thermo 
CO2incubator                BBD 6220 Thermo 
Diaphragm vacuum pump      MZ2C      Vacuubrand 
Electrophoresis chamber       Mini-Protean 3    Bio-Rad 
Electrophoresis chamber       Mini-Subcell GT   Bio-Rad 
Electrophoresis chamber       Subcell GT    Bio-Rad 
Electroporation device         PowerPac 200 Bio-Rad 
Electroporation device         PowerPac™ HC   Bio-Rad 
Gel imaging system           ChemiDoc™ XRS+ 
System 
Bio-Rad 
Graphing software            Graphpad prism 6 GraphPad 
Hot plate magnetic stirrer      RCT basic IKA 
Image analysis software        Image Lab™ Software Bio-Rad 
Incubation cabinet            U30 Memmert 
Microplate readers            Wallac 1420 Victor 2   Perkin Elmer 
Microscope                 TMS     Nikon 
Microscope                 Diaphot Nikon 
Mini Centrifuge              Galaxy mini C1213 VWR 
Mixer                      Vortex-Genie 2     IKA 
PH-meter SevenEasy™ Mettler-Toledo 
Pipettes                     Research® plus Eppendorf 
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Item  Model Manufacturer 
Precision balance             770     KERN 
Precision balance             440-45 N KERN 
Protein transfer device         Mini Trans-Blot Cell Bio-Rad 
Rolling mixer                RM5-35s 1732 Fröbel 
Shaker                     KS 125   IKA 
Shaker incubator             G25 Eppendorf 
Spectrophotometer NanoDrop ND-1000 PeqLab 
Thermal cycler               Primus 25 advanced PeqLab 
Thermal mixer               Thermomixer™ Eppendorf 
Ultra-Low temperature freezer  HFU 586 Basic          Thermo 
UV-transilluminator GEL iX20 INTAS 
Vacuum concentrator 5301 Eppendorf 




3.7.2 Chemicals and consumables 
Item  Product Number   Company 
100 bp DNA Ladder                N3231S     New England Biolabs 
4-PBA                           BML-EI320-0001 Enzo 
Agarose                          35-1020 PeqLab 
Blotting-grade blocker              1706404 BioRad 
Bovine Serum Albumin (BSA) 5482 Sigma-Aldrich 
Bromophenol blue B0126 Sigma-Aldrich 
Complete protease inhibitor cocktail 11836153001 Roche 
ddH2O  Central Warehouse 
Dichloromethane 106044 Merck-Millipore 
DL-Dithiothreitol (DTT) D0632 Sigma-Aldrich 
DNA Loading Dye, 6x R0611 Thermo 
DPBS                           14190     Gibco 
Ethanol, absolute (EtOH) 108543 Merck-Millipore 
Ethanol, technical (EtOH)  Central Warehouse 
Ethylene diaminetetraacetic acid 
(EDTA) E6758 Sigma-Aldrich 
Fetal bovine serum (FBS)            10500064   Invitrogen 
Glycerol                         G5516   Sigma-Aldrich 
Glycine                          3908.2 Roth 
H2O, sterile (Braun Aqua ad 
iniectabilia)  Central Warehouse 
HRP substrate Western Lightning 
Plus-ECL NEL103E001E Perkin Elmer 
LB-Agar                         X969.1 Roth 
LB-Medium                      X968.1 Roth 
Methanol                         32213     Sigma-Aldrich 
Mini-PROTEAN®                 
TGX Stain-Free™ Precast Gels 456-8123 Bio-Rad 
NADPH                          N1630   Sigma-Aldrich 
Nonidet P 40                      74385   Fluka 
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Item  Product Number   Company 
Page Ruler prestained protein ladder   26616     Thermo 
Paraffin                          107337   Merck-Millipore 
Penicillin / streptomycin (Pen-Strep)   15140 Invitrogen 
Phenylmethanesulfonylfluoride 
(PMSF)          
P2721    DiaSorin 
PVDF membrane                  IPVH00010 Merck-Millipore 
RNase-free water                  129112 Qiagen 
RotiQuant 0118.2    Roth 
RPMI 1640                       61870 Gibco 
Sodium chloride (NaCl)             1064040500   Merck-Millipore 
Sodium lauryl sulfate(SDS) L3771 Sigma-Aldrich 
Tris base                         T6606 Sigma-Aldrich 
Tween 20                        P1379   Sigma-Aldrich 
3.7.3 Buffers and solutions 
3.7.3.1 Buffer 
RIPA Buffer 
Component Final concentration 
EDTA pH 8 [0.5 M] 1 mM 
NaCl [2.5 M] 150 mM 
NP-40 1% 
Tris pH7.4 [1M]  50mM 




5x Running Buffer 
Component Final concentration 
Glycine 1 M 
SDS [10%] 0.5 % 
TrisBase 125 mM 
 
Transfer Buffer 
Component Final concentration 
Glycine 0.2 M 
Methanol 20 % 
TrisBase 25 mM 
 
4x TBS (pH 7.6)     
Component Final concentration 
NaCl 0.5 M 
TrisBase 80 mM 
The buffer was adjusted the pH to 7.6 using 1 M HCl and kept at 4°C. 
1 x TBS (pH 7.6)     
Component Final concentration 
NaCl 0.5 M 
TrisBase 80 mM 
Tween 0.1 % 





SDS sample buffer (6x)  
Component Final concentration 
Bromophenol blue 0.06 % 
DTT 0.6 M 
Glycerol 30% 
SDS 12 % 
Tris pH6.8 [0.5M] 0.06 M 
The solution was stored as aliquots at -20 °C. 
3.7.3.2 Solution 
Solution Concentration 
1st antibody solution 1:6,667 in blotting-grade blocking solution 
2nd antibody solution 1:10,000 in blotting-grade blocking solution 
4-PBA stock solution 100 mM in nuclease-free water with filtration 
Ampicillin stock solution 100 mg/ml in nuclease-free water with filtration 
Blotting-grade blocking solution   10 % in 1x TTBS 
BSA solution 10 mg/ml in proteinase inhibitor solution 
LB medium 25 g/l in ddH2O 
PMSF solution 4 mM in absolute ethanol 
Proteinase inhibitor solution one tablet for 10 ml RIPA buffer 






Item Product Company 
PureYield™ Plasmid Midiprep System A2495 Promega 
PureYield™ Plasmid Miniprep System A1222 Promega 
QuickChange site directed mutagenesis kit 200518 Agilent Technologies 
3.8 Statistical analyses 
Values are expressed as mean ± standard error of mean (SEM). Unpaired two-sample 





Through limited proteolysis by proteinase K experiment, we finally calculated 
half-lives of WT and all variant proteins. Compared with WT, all variant proteins 
showed reduced half-lives (p < 0.05 or < 0.01), indicating that CYP21A2 variant 
enzymes were more susceptible to degradation by protease K (Figure 5, Table 2). 
Substantially reduced half-lives were detected in the variant proteins P30Q, G90V, 
R356W and R483W, which had half-lives less than 1min.  
We then determined mean half-lives of WT and variant proteins after cells had been 
cultivated at 37°C and 30°C (Figure 5). A student’s T-test showed there was no 
difference in half-lives of WT, I172N, V281G, V281L, D322G, G375S and P453S at 
the different temperatures (p>0.05). Other variant proteins (P30L, P30Q, G90V, 
R356Q, R356W, R483Q and R483W) showed significantly longer half-lives (p < 0.05 
or < 0.01) at 30°C degree. This result suggested that reduced temperature could 
stabilize some but not all variant proteins and prevent them from rapid degradation. 
We then examined whether the chemical chaperone 4-PBA influences the half-lives of 
CYP21A2 variant proteins (Figure 6, Table 2). For these experiments, we chose WT 
and variant proteins which had a prolonged half-life after cells had been cultivated at 
30 °C. If these proteins can be also stabilized by reduced temperature and 4-PBA, it 
will illustrate that the rescue was specific for a limited set of variant proteins. 
Furthermore, we also selected I172N for further investigations although we did not 
observe an effect of temperature here as this is a clinically highly relevant protein 
variant and as others have shown altered conformation of the I172N mutant protein by 
increasing concentrations of proteinase K digestion previously (Hsu et al., 1996). As 
shown in the histogram half-lives of all variant proteins except I172N were prolonged 
by 4-PBA (p < 0.05 or < 0.01), and interestingly two (R356Q and R483W) of them 
even had longer half-lives than WT, indicating that 4-PBA can markedly enhance the 
half-life of some variant proteins. WT and I172N did not show any augment on 
half-lives (p>0.05), which fits to our previous observation that I172N did not show 
any change in half-life based on different temperature. In summary, 4-PBA treatment 
31 
 
induced a significant effect on stabilization of some CYP21A2 variant proteins. The 
respective Western Blot results are summarized in Figure 7. These figures show 
representative Western Blot results and the calculated protein decay curves resulting 
from the proteinase K experiments described above. All calculated half-lives are 
given also in Table 2. Overall, reduced half-life caused by CYP21A2 protein variants 
could be reversed by reduced temperature and 4-PBA treatment. 
 
 
Figure 5 Half-lives of WT and variant proteins at 37°C and 30°C in minutes. 
Degradation of the WT and variant proteins were probed by western-blotting 
analyses. Densitometric analysis was performed using Imagequant software. Half-life 
was calculated using a one-phase exponential decay model and given in mean ± SEM 
of n= at least 3 independent experiments. Black bar represented half-life at 37°C, 
while grey bar indicated half-life at 30°C. # - p<0.05, ## - p<0.01 denote significant 
differences of the half-lives of variant proteins at 37°C compared with the half-life of 
WT at 37°C.* - p<0.05, ** - p<0.01 denote significant differences of the half-life at 




































Figure 6 Half-lives of WT and variant proteins with and without 4-PBA treatment. 
Each value represents mean ± SD of three independent experiments performed. Black 
bars represent half-life without 4-PBA treatment, while white bars indicate half-life 
with 1 mM 4-PBA treatment. * - p<0.05, ** - p<0.01 denote significant differences 
compared with the corresponding no treatment group. ## - p<0.01 denotes significant 
































































































Figure 7 Effect of reduced temperature and 4-PBA on WT and variants CYP21A2 
protein against limited proteolysis by proteinase K. A to I columns represent 
degradation curves and representative western blot images of WT and variant 
proteins after treatment of 37°C, 30°C and 4-PBA respectively. CYP21A2 protein was 
detected with western blot immunoprecipitated from cell lysates as described in the 
materials and methods section and the blot shown was a representative fluorography 
from at least three independent experiments. Protein bands from the immunoblots 
were quantitated with Image J software. The values were expressed as percent of t = 
0 chase time that was set to 100%. Error bars represented the standard error of mean 



















WT 8.3 min±0.6 7.7 min±0.7 0.534 7.2 min±0.6 6.6 min±0.5 0.538 
P30L 1.3 min±0.1 5.5 min±0.4 0.000 1.2 min±0.1 2.6 min±0.2 0.004 
P30Q 0.9 min±0.1 8.0 min±0.8 0.001 0.8 min±0.1 1.3 min±0.1 0.016 
G90V 0.9 min±0.2 5.9 min±0.4 0.000 0.6 min±0.0 5.4 min±0.2 0.000  
I172N 1.4 min±0.2 1.4 min±0.2 0.979 1.6 min±0.2 1.2 min±0.2 0.297 
V281G 2.4 min±0.1 2.8 min±0.1 0.063    
V281L 6.2 min±0.4 4.8 min±0.3 0.060    
D322G 3.8 min±0.2 2.9 min±0.6 0.191    
R356Q 1.0 min±0.1 2.1 min±0.2 0.009 1.0 min±0.1 6.5 min±0.1 0.000  
R356W 0.6 min±0.0 9.8 min±0.6 0.004 0.6 min±0.0 11.7min±0.8 0.000  
G375S 4.0 min±0.4 3.8 min±0.4 0.746    
P453S 5.7 min±0.5 6.5 min±0.6 0.369    
R483Q 2.4 min±0.0  3.1 min±0.0 0.000  2.3 min±0.2 12.6 min±0.9 0.000  






5.1 The correlations between protein half-lives and clinical phenotypes and molecular 
mechanisms 
We studied protein degradation by investigating protein half-lives, to enhance the 
understanding of the molecular mechanism of 21-OHD. We chose 13 naturally 
occurring mutations in which we speculated from in silico modeling to be possibly 
related with protein instability. We investigated their susceptibility against proteinase 
K. We found that all variant proteins showed decreased stability to proteinase K 
compared with WT, suggesting that the instability speculating from the in silico 
modelling based on the crystal structure can be confirmed. Moreover, molecular 
characterization of CYP21A2 protein variants can provide comprehensive structural 
explanations for clinical phenotype based on changes it brings in the structure of the 
protein (Haider et al., 2013). However, few functional studies have ever been 
performed to prove the structure-function relationship. Our results show for the first 
time that loss of half-lives of most variant proteins were in agreement with severity of 
the clinical phenotype. Different molecular mechanisms of each mutation that induce 
the structural instability and the correlation between protein half-life and phenotype 
are discussed below. 
5.1.1 Impairment of hydrophobic interactions 
Some residues have hydrophobic interactions with other residues from different 
structural elements to maintain the organization of secondary structures of protein. 
The mutations of these residues will disrupt the hydrophobic network and thus impair 
stability of the protein.  
P30L and P30Q: In the present study, P30Q showed dramatically decrease of 
half-life shorter than 1min, and P30L had a longer half-life than P30Q, indicating that 
P30Q was less stable than P30L (Table 4). Patients with P30L and P30Q were found 
to present NC and SW phenotype respectively (Lajic et al., 1999; Tusie-Luna et al., 
1991). Structural explanations for these two mutations are provided by crystal 
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structure. Since P30 is lodged in a hydrophobic cavity and help attach the P450 to the 
membrane, when substituted to the hydrophilic residue glutamine, it will cause a 
disruption of hydrophobic network disruption, induce steric conflicts with I59 and 
V70 (Figure 8A), and probably affect the flexibility of the tether between P450 and 
the membrane (Pallan, Lei, et al., 2015). When proline is substituted by leucine, 
another hydrophobic residue, it leads to less improper folding of the polypeptide and 
is better tolerated than glutamine, leading to milder form of 21-OHD (Haider et al., 
2013). The half-life of P30Q in our study is compatible with the SW phenotype, but 
half-life of P30L is shorter than other variant proteins which had NC phenotype. 
Several functional studies showed that P30L caused only 40-70% loss of CYP21A2 
enzyme activity in vitro and was related with the NC form (Marino et al., 2011). 
However, New et al. found that over 30% P30L-carrying patients presented with 
classical 21-OHD (M. I. New et al., 2013). Another study investigated the 
manifestation of patients with P30L mutation and found that compared with other NC 
patients, it produced more severe signs, including clitoromegaly (Tusie-Luna et al., 
1991). Therefore, the spectrum of P30L is extremely wide. In addition, P30L may 
interfere with localization to the endoplasmic reticulum, which could have a further 
influence on the stability of enzyme than other NC variant proteins. 
I172N: The phenotype of I172N is SV (Amor, Parker, Globerman, New, & White, 
1988). The half-life of I172N in our study showed an obvious reduction but higher 
than those of SW variant proteins, which was consistent with the phenotype of I172N. 
Hsu et al. also used proteinase K to digest WT and I172N from yeast microsomes and 
found higher sensitivity of the I172N protein than WT toward proteinase K digestion 
(Hsu et al., 1996). I172 sits in helix E and is surrounded by M186 and M187 residues 
of F-helix. The isoleucine residue at the position of helix E is highly conserved and 
located in a hydrophobic pocket (Figure 8B). Substitution of the hydrophobic residue 
isoleucine to hydrophilic residue asparagine might disrupt the intramolecular 
hydrophobic interactions, leading the destabilizing of secondary structure of enzyme 
(Pallan, Lei, et al., 2015; White & Speiser, 2000).  
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V281L and V281G: Our experiment demonstrated that half-life of V281G was 
significantly shorter than that of WT, but longer than those of all SW proteins we 
measured, whereas that of V281L was slightly lower than WT, which in line with the 
phenotypes of V281L and V281G are NC and SV respectively (Lajic, Robins, Krone, 
Schwarz, & Wedell, 2001; Speiser, New, & White, 1988). V281 sits on the helix I and 
forms a hydrophobic patch together with helix H amino acids M258, M261, L262, 
and V265  (Figure 8C). When substituted from V to G, it will disrupt the interaction 
causing the impairment of protein stability. Moreover, the helix is also rendered 
unstable because of the high conformational flexibility imparted by glycine. When 
substituted to leucine, although increase in chain length leads to steric clashes, the 
influence on stability is relatively modest as leucine is a hydrophobic residue as well 
(Haider et al., 2013).  
P453S: Only a slightly diminished half-life was shown in stability of P453S 
compared with WT, as expected of the mild clinical phenotype (Helmberg, 
Tusie-Luna, Tabarelli, Kofler, & White, 1992). P453 is positioned in a hydrophobic 
pocket surrounded by L308 (I-Helix), L452 (β8-sheet), L458 (β8-β9 loop). Proline is 
important for the secondary structure of this region due to the hydrophobic pocket 
where proline sits and the rigidity it introduces to the sharp turn (Figure 8D). 
Substitution to serine might disrupt hydrophobicity of this region and then misalign 
the sharp turn, resulting NC 21-OHD.  
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A                                 B                    
C                                  D                                                
Figure 8 Detailed local structural features of CYP21A2 variants which have 
impairment of hydrophobic interactions or introduction of bulkier residue. (A) 
P30Q and G375S, (B) I172, (C) V281, and (D) P453. Residues are colored in 
magenta. 
5.1.2 Impairment of salt bridges and hydrogen bonds 
In addition to hydrophobic network, CYP21A2 protein also has many salt bridges and 
hydrogen bonds which are crucial for the stability of tertiary structure of the enzyme. 
D322G, R483Q, and R483W: Like other SW variant proteins, R483W had the 
highest reduction in half-life. On the contrary, D322G and R483Q showed obviously 
higher stability than R483W. They are in line with their phenotypes (Bleicken et al., 
2009; Kharrat et al., 2004; T. Robins et al., 2007; Stikkelbroeck et al., 2003). From 
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the crystal structures, R483 and D322 are related since there is a salt-bridge formation 
between them through the polar charged residues (Figure 9A). Therefore, when 
arginine is substituted to glutamine/tryptophan or aspartic acid is substituted to 
glycine, it will prevent the salt-bridge formation and subsequently affect stability of 
tertiary structure (Haider et al., 2013). Since tryptophan is nonpolar and uncharged 
residue, R483W may disrupt the salt-bridge completely and affect enzyme stability 
severely, so it is comprehensible that R483W leads to SW phenotype. On the contrary, 
glutamine and aspartic acid are both polar and uncharged residues and better tolerated 
than tryptophan, so D322G and R483Q cause milder phenotypes.  
R356Q and R356W: The results of the present study clearly demonstrated that 
R356W showed the most severe instability while R356Q was less instable than 
R356W but still less stable than WT (Table 4). They are both in agreement with their 
clinical phenotypes. R356 (K-helix) forms a hydrogen bonding with Q389 (K’-helix) 
and Q462 (β8-β9). The hydrogen bonding plays a role in maintaining spatial 
conﬁguration and tertiary structure of the CYP21A2 enzyme (Figure 9B) (Haider et 
al., 2013). When R356 is substituted to hydrophobic tryptophan, it will completely 
disrupt the hydrogen bonding, so that R356W exhibits SW 21-OHD. However, its 
substitution to hydrophilic glutamine, the hydrogen bonding is partly lost, resulting in 
SV 21-OHD.  
G90V: The half-life of G90V we measured was rather short and compatible with the 
phenotype SW. G90 is located in B-B’ loop adjacent to R91 (Figure 9C). The 
substitution of valine residue would indirectly introduce inflexibility to the loop 
through influence on hydrogen bond of R91 with the propionate side chains of heme, 
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Figure 9 Detailed local structural features of CYP21A2 variants which have 
impairment of salt bridges and hydrogen bonds. (A) D322 and R483, (B) R356, and 
(C) G90. Residues are colored in magenta. 
5.1.3 Introduction of bulkier residue 
Protein instability also occurs when introduction of bulkier residues lead to 
destabilization of the secondary structure. 
G375S: The phenotype of patients with G375S is SW (Lajic et al., 2002). However, 
the half-life (4.0min±0.6) we measure was not in agreement with the phenotype. It 
45 
 
was longer than all variant proteins of SW and SV and slightly lower than WT. Such 
an inconsistent result was also found in another study. Svetlana Lajićel al. also 
investigated half-life of G375S by blocking of translation using cycloheximide and 
analyzing proteins at different time points (0, 4, 8, 12, and 24 h) and found half-life of 
WT (13.0 h; minimum, 7.8 h; maximum, 23.6 h) has not great difference with that of 
G375S (10.7 h; minimum, 8.3 h; maximum, 14.1h), concluding that function of 
G375S was impaired more than overall structure (Lajic et al., 2002). The crystal 
structure reveals that G375 is present on the turn of β5-β6 hairpin. β5-β6 is only 
suitable for small residue. However, when substituted to serine, increased rigidity 
results in less conformational flexibility and hence reduces protein stability (Figure 
8A).   
In summary, most results of the present study are consistent with reported phenotypes, 
indicating good correlation between function and structure. Moreover, the location of 
CYP21A2 protein variants can provide a general understanding of structure-function 
relationship. However, there are still some exceptions, so we speculate that 
loss-of-function may be not always be explained by structure. 
5.2 Role of reduced temperature and 4-PBA in protein stability 
Importantly, our research demonstrated that stability of seven variant proteins can be 
enhanced by reduced temperature and chemical chaperone 4-PBA. It is the first time 
to explore reduced temperature and chemical chaperone as potential therapeutic tools 
for CYP21A2 protein variants in vitro. The results substantiate our hypothesis of 
protein misfolding with loss-of-function as a relevant molecular mechanism in 
21-OHD that can be addressed by structural stabilization of CYP21A2 protein 
variants. Reduced temperature and 4-PBA have been applied in experiments with 
many different variant proteins and underlying mechanisms have been investigated. 
5.2.1 Reduced temperature 
It is long considered that protein folding and processing are temperature-sensitive 
(Powell & Zeitlin, 2002). In 1990, one study showed that, at reduced temperature 
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(19-33°C), H-2/beta 2-microglobulin complexes was promoted assembly, resulting in 
a high level of cell surface expression (Ljunggren et al., 1990). After that, increasing 
variant proteins have been confirmed as temperature-sensitive proteins. In order to 
explore the influence of reduced temperature on the protein synthesis, Heda and 
Marino investigated CFTR mRNA level at 27°C and found there was no increase 
(Heda & Marino, 2000). The molecular mechanisms of reduced temperature treatment 
are: (i) Reduced temperature helps the variant proteins escaping the ER quality 
control system so that degradation is inhibited. Such effect has been observed for 
α1-ATZ in CJZ12B cells. When the temperature was reduced from 37°C to 27°C, it 
was clear to see a significant decrease in degradation at 27°C by pulse-chase radio 
labeling (Burrows et al., 2000). A similar conclusion was obtained by some other 
studies in PrP187R and V2R-V206D at low temperature (Gu & Singh, 2004; Robben et 
al., 2006). (ii) Lowering the temperature can contribute to partial folding of protein in 
the ER. Sharma el al. found at least some of the chains of ∆F508CFTR were properly 
assembled by the cellular machinery at reduced temperature (Sharma, Benharouga, 
Hu, & Lukacs, 2001). (iii) Reduced temperature also plays an important role in 
facilitating protein expression in targeted subcellular organelles. It has been shown 
that after incubation of ∆F508C127 cells at 27°C for 60h, biochemical and functional 
expression of ∆F508CFTR at the cell surface was increased (Heda & Marino, 2000). 
Some previous studies also have demonstrated that low temperature promotes some 
other disease-associated mutants such as PrPQ271R and PrP187 trafficking and 
functioning at the plasma membrane (Gu & Singh, 2004; Singh et al., 1997). As our 
experiment found, some variant proteins of CYP21A2 can be stabilized at 30°C, 
revealing that CYP21A2 protein is temperature-sensitive. We speculate that low 
temperature plays a vital role in reducing degradation, strengthening folding and 
increasing expression on ER membrane, but this needs further research. 
5.2.2 Chemical chaperone 4-PBA 
4-PBA has been shown in a number of studies that it can stabilize proteins that 
contain folding defects. Unlike reduced temperature, 4-PBA can enhance protein 
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expression. Heda and Marino demonstrated that 4-PBA can increase ∆F508 mRNA 
levels and protein expression (Heda & Marino, 2000). Similarly, another study also 
found that ABCA1 protein expression was increased via treatment with 4-PBA in all 
transfected cell lines (Sorrenson et al., 2013). Therefore, in our experiment, half-lives 
of R356W and R483Q are prolonged more than that of WT can be explained likely 
because of increased protein expression by 4-PBA treatment. 
In addition, 4-PBA is believed to be of importance on prevention of aggregation of 
variant proteins, rescue of protein localization and restoration of functional proteins in 
many researches. By counting 293T cells bearing intracellular HFEC282Y aggregates, 
it was observed that after treated with 4-PBA, the percentage of cells with aggregates 
were remarkably decreased, which means that 4-PBA can prevent HFEC282Y 
aggregation (de Almeida et al., 2007).In studies of 4-PBA treatment on CFTR variant 
proteins responsible for cystic ﬁbrosis, researchers have demonstrated that 4-PBA 
ameliorated ER retention and was sufficient to restore protein function in vitro and in 
vivo (R C Rubenstein et al., 1997; Zeitlin et al., 2002). The mechanism of 4-PBA 
function has been not completely understood; some studies thought it may act due to 
its effect on regulating cellular molecular chaperones. 4-PBA could downregulate 
protein and mRNA expression of the heat shock cognate protein HSC70 was observed 
in 4-PBA-treated IB3-1 cells (R. C. Rubenstein & Lyons, 2001). HSC70 is widely 
believed to take part in ubiquitin-dependent degradation of a number of intracellular 
proteins (Bercovich et al., 1997). Accordingly, 4-PBA can inhibit ubiquitination and 
subsequent degradation by the proteasomal system through inducing HSC70. 
Furthermore, there are a few studies that also found Hsp70 expression increasing after 
4-PBA treatment (Choo-Kang & Zeitlin, 2001; Garcia-Bermejo et al., 1997; Gong, 
Zhang, Lam, Pang, & Yam, 2010). This could be beneficial for protein disaggregation, 
folding and complex remodeling, trafficking and maturation (Liberek, Lewandowska, 
& Zietkiewicz, 2008; Teter et al., 1999; Zhang et al., 2001; Zietkiewicz, 
Lewandowska, Stocki, & Liberek, 2006). As mentioned before, molecular chaperones 
also participate in the biogenesis of CYP21A2 protein. Although whether 4-PBA can 
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influence molecular chaperones is unclear, we could confirm that 4-PBA is beneficial 
for further processing of variant proteins. 
Overall, some molecular mechanisms may be involved in actions of reduced 
temperature and chemical chaperone 4-PBA. However, the underlying molecular 
mechanisms of reduced temperature and 4-PBA on CYP21A2 variant proteins folding, 
disaggregation, trafficking and maturation, needs further investigation. 
5.3 Mutation speciﬁc rescue of CYP21A2 variant proteins 
The results of the present study clearly demonstrated that susceptibility to proteinase 
K of several variant proteins were not improved after reduced temperature and 4-PBA 
treatment, which illustrated that the rescue was not a general phenomenon but specific 
for a limited set of variant proteins. Robben el al. tested nine V2R mutants and found 
that treatment with chemical chaperones only rescued plasma membrane expression 
and increased receptor maturation of V2R-V206D (Robben et al., 2006). Similar 
results have been also shown in chemical chaperone treatment on HERG and CFTR 
mutants (Delisle et al., 2003; Sato, Ward, Krouse, Wine, & Kopito, 1996). The 
underlying mechanism is still unclear. From our results that all variant proteins from 
the same position (P30L and P30Q, R356Q and R356W, R483Q and R483W) were 
stabilized, we speculated that the ability to be rescued by temperature and chemical 
chaperones may be dependent upon the localization of residues in the protein structure 
of CYP21A2, but further studies are needed. 
5.4 Perspective 
Current experiments only investigated improvement of CYP21A2 protein variants 
stability but not activity by reduced temperature and chemical chaperone 4-PBA. 
Therefore, the next logical step it to measure enzyme activity to functionally 
characterize variant proteins and investigate the effect of reduced temperature and 
4-PBA on activity. Furthermore, through comparison of enzyme stability and activity, 
a better understanding of its structure-function relationship can be achieved. We have 
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gained a few preliminary data on this aspect but this needs to be studied in future 
experiments. 
As mentioned before, 4-PBA has been tested in Phase I clinical trials and oral 
administration of 4-PBA was well tolerated. These studied demonstrated that 4-PBA 
is a viable therapeutic approach for protein misfolding diseases (Burrows et al., 2000; 
R. C. Rubenstein & Zeitlin, 1998; Zeitlin et al., 2002). Thereby, further studies can 
investigate 4-PBA improvement on enzyme function and structure in vivo and 
subsequently phenotypes of patients. 
Besides chemical chaperones inducing a stabilizing effect as non-specific binders, 
there are pharmacological chaperones which can selectively target variant proteins to 
achieve a more stable state. Pharmacological chaperones can provide molecular links 
or bridges to compensate for the loss of stabilizing interactions and introduction of 
destabilizing interactions caused by the mutation. Due to the characteristics of high 
specificity and affinity, pharmacological chaperones therapy becomes a developing 
area in the treatment of protein misfolding diseases arising from genetic mutations 
(Arakawa, Ejima, Kita, & Tsumoto, 2006; Ulloa-Aguirre, Janovick, Brothers, & Conn, 
2004). Since unstable structure of CYP21A2 variant proteins was found in molecular 
modeling, pharmacological chaperones therapy may be a potential approach in the 
future. Identification of potential pharmacological chaperones are firstly required by 
high-throughput screening and rational design, and then enzyme stability and activity 
can be tested in cell models treated with selected pharmacological chaperones. It 
would be a long term task but extremely rewarding for 21-OHD treatment with the 





Congenital adrenal hyperplasia (CAH) is a group of autosomal recessive disorders 
characterized by impaired synthesis of cortisol. 21-hydroxylase deficiency (21-OHD), 
the most common form of CAH, is caused by defects of the CYP21A2 gene and 
constitutes a life-threatening disease. Patients with 21‐OHD experience significant 
health concerns due to co-morbidities which are often treatment-related. Therefore 
current treatment strategies, which consist of steroid replacement, are unsatisfying. 
New causative treatment options with the least risk of side effects are needed. 
Based on the research of other diseases investigating protein misfolding as underlying 
pathophysiological mechanism such as cystic fibrosis or phenylketonuria, we 
hypothesize that also 21-OHD in part is a protein misfolding disease. In silico 
modelling suggested protein instability and misfolding to play a significant role in the 
pathogenesis of 21-OHD. Thus, in this research, we investigated 13 variant proteins 
which are caused by point mutations and speculated from in silico modelling to be 
related with impaired protein stability. The selected variant proteins cover all three 
phenotypes of 21-OHD and do not cause direct disruption of heme and/or substrate 
binding. The influence of 4-PBA and reduced temperature on variant protein half-life 
(susceptibility to proteinase K) was investigated. We found that all variant proteins 
showed reduced half-lives compared with WT, indicating that CYP21A2 variant 
enzymes were more susceptible to degradation by protease K. Reduced temperature 
and 4-PBA could stabilize some but not all variant proteins, which illustrated that the 
rescue was not a general phenomenon but specific for a limited set of variant proteins. 
There were seven variant proteins P30L, P30Q, G90V, R356Q, R356W, R483Q and 
R483W which could be stabilized by both approaches.  
Our data substantiated the hypothesis of protein instability as a relevant molecular 
mechanism in 21-OHD that can be addressed by structural stabilization of CYP21A2 
variant protein. These strategies above may provide new avenues in 21-OHD 





Das Adrenogenitale Syndrom (AGS) ist eine Gruppe autosomal-rezessiver 
Erkrankungen, die durch die beeinträchtige Synthese von Cortisol gekennzeichnet ist. 
Der 21-Hydroxylase-Mangel (21-OHD), die häufigste Form des AGS, beruht auf 
einem Defekt des CYP21A2-Gens, was zu einer lebensbedrohlichen Krankheit führt. 
Patienten mit 21-OHD sind von erheblichen gesundheitlichen Problemen betroffen, 
die oftmals als Begleiterkrankungen durch die Therapie auftreten. Die aktuell zur 
Behandlung eingesetzte Hormonersatztherapie ist somit nicht zufriedenstellend. Es 
werden neue kausale Therapieansätze mit einem geringeren Risiko für 
Nebenwirkungen benötigt. 
Basierend auf Forschungsarbeiten anderer Erkrankungen wie der zystischen Fibrose 
oder Phenylketonurie, bei welchen Proteinfehlfaltung als zugrundeliegender 
Pathomechanismus eine wichtige Rolle spielt, hat diese Arbeit die Hypothese, dass 
auch der 21-OHD zum Teil durch Proteinfehlfaltung bedingt ist. In einem in silico 
Modell untersuchten wir, ob Proteininstabilität und Fehlfaltung eine entscheidende 
Rolle in der Pathogenese des 21-OHD spielen könnte. Folglich werden in dieser 
Forschungsarbeit 13 verschiedene Proteinvarianten untersucht, die auf Grund des in 
silico Modells mit einer verminderten Proteinstabilität in Verbindung gebracht werden 
können. Die ausgewählten Proteinvarianten, schließen zum einen alle drei Phänotypen 
des 21-OHD mit ein, zum anderen unterbrechen sie nicht die Bindung des Häms 
und/oder des Substrats. Der Einfluss von 4PBA und einer verminderten Temperatur 
auf die Halbwertszeit der verschiedenen Varianten des Proteins (Suszeptibilität 
gegenüber Proteinase K) wurde untersucht. Wir haben herausgefunden, dass alle 
Proteinvarianten im Vergleich zum Wildtyp eine verminderte Halbwertszeit zeigten, 
was darauf hinweist, dass die CYP21A2 Enzymvarianten anfälliger für den Abbau 
durch Proteinase K waren. Eine verringerte Temperatur und 4-PBA konnte manche, 
aber nicht alle der Proteinvarianten stabilisieren, wodurch gezeigt wurde, dass die 
Stabilisierung nicht ein generelles Phänomen, sondern nur spezifisch auf eine 
begrenzte Zahl der Proteinvarianten zutraf. Es gab sieben verschiedene 
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Proteinvarianten, P30L, P30Q, G90V, R356Q, R356W, R483Q und R483W, die 
durch beide Methoden stabilisiert werden konnten.  
Unsere Daten untermauern die Hypothese der Proteinstabilität als relevanter 
molekularer Mechanismus des 21-OHD, dem mit einer strukturellen Stabilisierung 
des CYP21A2 begegnet werden kann. Diese Strategien könnten neue Wege für die 
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Three‐dimensional  structure  of  steroid  21‐hydroxylase  (cytochrome  P450  21A2)  with  two 











Protein (WT and variants) Time (min) 0 0.5 1 2 5 10 30 60 120 
WT 37°C 1st 4957632 3207204 1953612 2391084 3035772 1672920 770400 171936 260460 
 2nd 4102138 4292366 4742362 4450218 3233534 2935234 1940052 2015406 3251926 
 3rd 3711688 4427988 3898230 4937948 2767464 3996384 685216 768094 362862 
 AVG 4257153 3975853 3531401 3926417 3012257 2868179 1131889 985145 1291749 
 SEM 367929 386313 825672 780471 135056 671564 404829 543117 980534 
WT 30°C 1st 5302044 3702744 3305736 3275676 2803844 2319996 1302984 820656 199188 
 2nd 4135934 4026969 3172787 3057384 2569613 2182445 1238575 907943 235801 
 3rd 4965972 4327690 3045754 5213186 2042312 2147746 854896 618936 117810 
 AVG 4801317 4019134 3174759 3848749 2471923 2216729 1132152 782512 184266 
 SEM 346548 180449 75057 685123 225196 52596 139869 85581 34869 
WT 4PBA treated 1st 3331746 2939079 1509849 1553805 1380027 1502457 212784 37323 16764 
 2nd 4502470 3772615 2418150 3074820 2116485 1828085 348390 340021 126420 
 3rd 5027580 3123614 3102942 3700152 2206328 2007802 366792 11458 17884 
 AVG 4287265 3278436 2343647 2776259 1900947 1779448 309322 129601 53689 
 SEM 501231 252767 461393 637327 261748 147894 48560 105475 36367 
P30L 37°C 1st 5601097 5850699 3066893 2280236 1450215 1262107 1054833 301920 81696 
 2nd 8399330 5743586 5133040 4016334 3528300 1788052 2510850 1196848 1490246 
 3rd 6887402 4160687 4506526 4759199 2747324 2647239 2314091 2222590 2675507 
 4th 3276315 1958040 2047535 1582875 1512140 1408365 806260 642775 397060 
 5th 5739812 5121794 4256358 3451612 3314932 3880352 2481728 2458234 2040374 
 AVG 6656910 5219192 4240704 3626845 2760193 2394438 2090376 1544898 1571956 
62 
 
Protein (WT and variants) Time (min) 0 0.5 1 2 5 10 30 60 120 
 SEM 648393 387697 432532 522653 466720 571673 347893 496620 552629 
P30Q 37°C 1st 5512519 2320196 3270023 2541382 1486253 1811927 1393087 746697 338735 
 2nd 1567468 2339302 1877378 1658044 1642472 1040604 317254 111792 26860 
 3rd 4524414 5259800 3785050 3057586 3757918 1968600 1123326 1893188 1059066 
 AVG 5018467 3306433 2977484 2419004 1564363 1607044 944556 917226 474887 
 SEM 1972526 976699 569792 408620 78110 286808 323173 521265 305650 
P30L 30°C 1st 4102138 4292366 4742362 4450218 3233534 2935234 1940052 2015406 3251926 
 2nd 6377105 6511435 5355525 6332585 3157175 3206560 1837080 1660225 989205 
 3rd 6814844 5682406 7036270 4993088 3998498 2543264 1314116 1586196 737124 
 AVG 5764696 5495402 5711386 5258630 3463069 2895019 1697083 1753942 1659418 
 SEM 840828 647378 685682 559378 268620 192530 193777 132467 799572 
P30Q 30°C 1st 1751832 1290744 1303236 872064 1179720 733320 1353852 415656 157968 
 2nd 1567468 2339302 1877378 1658044 1642472 1040604 317254 111792 26860 
 3rd 2134049 1149442 1316719 1319124 1219742 1211935 434380 556369 375291 
 AVG 1942941 1815023 1499111 1283077 1347311 995286 375817 361272 186706 
 SEM 191109 524279 189174 227608 148032 140010 58563 131187 101605 
P30L 4PBA treated 1st 4102138 4292366 4742362 4450218 3233534 2935234 1940052 2015406 3251926 
 2nd 6377105 6511435 5355525 6332585 3157175 3206560 1837080 1660225 989205 
 3rd 6814844 5682406 7036270 4993088 3998498 2543264 1314116 1586196 737124 
 AVG 5764696 5495402 5711386 5258630 3463069 2895019 1697083 1753942 1659418 
 SEM 1010279 761902 634195 322200 289135 390067 356366 878836 1376534 
P30Q 4PBA treated 1st 1751832 1290744 1303236 872064 1179720 733320 1353852 415656 157968 
 2nd 1567468 2339302 1877378 1658044 1642472 1040604 317254 111792 26860 
 3rd 2134049 1149442 1316719 1319124 1219742 1211935 434380 556369 375291 
 AVG 1942941 1815023 1499111 1283077 1347311 995286 375817 361272 186706 
63 
 
Protein (WT and variants) Time (min) 0 0.5 1 2 5 10 30 60 120 
 SEM 357448 1422953 299440 781958 659440 948814 271699 217913 473796 
G90V 37°C 1st 7151616 3333678 3459296 2871392 2051840 1426656 459744 57312 19968 
 2nd 4360125 1602579 2455101 1553112 1134408 632412 126489 28545 19635 
 3rd 2997088 2290176 748256 1011424 499680 1107424 470944 424000 350560 
 4th 2589928 2527470 1296108 1696563 2119491 986733 701646 293667 761739 
 AVG 4274689 2438476 1989690 1783123 1451355 1038306 439706 200881 287976 
 SEM 1030966 357074 605431 391604 388708 164064 118355 95177 176116 
G90V 30°C 1st 1224704 1320544 1851776 1078400 747008 506752 242752 9184 18496 
 2nd 2072140 1897840 1853478 1333840 1119780 847230 200760 52395 148610 
 3rd 2091111 1218492 1379103 1880676 836121 842919 405867 373923 204699 
 4th 2390916 2724348 1290003 1669074 1451274 1315908 542223 463386 110451 
 5th 2556736 1660640 2143104 1842560 1207776 778560 206656 235264 218624 
 AVG 2067121 1764373 1703493 1560910 1072392 858274 319652 226830 140176 
 SEM 229656 268803 160303 154540 127637 130328 67003 88166 36110 
G90V 4PBA treated 1st 4926510 4010482 3421292 5445400 3055162 2426832 1863444 924350 1720108 
 2nd 5720208 7106463 7220772 6299631 3387657 4341363 2349906 3361137 1811121 
 3rd 4880016 3351888 1852776 2511396 2966508 2309040 2034000 1735092 434664 
 AVG 5175578 4822944 4164947 4752142 3136442 3025745 2082450 2006860 1321964 
 SEM 272646 1157480 1593593 1147190 128188 658687 142504 716444 444427 
I172N 37°C 1st 5704560 6235092 3787452 3214260 3838068 2205720 2438424 3136932 1432296 
 2nd 5801565 6499745 3906280 3388700 2141685 2789395 2987005 2022930 1946483 
 3rd 7084152 7804044 7275564 4303872 4963068 3546180 3655728 3317004 3007872 
 AVG 6196759 6846294 4989765 3635611 3647607 2847098 3027052 2825622 2128884 
 SEM 444579 484931 1143414 337904 820012 388032 351975 404698 463883 
I172N 30°C 1st 7133526 4830535 3024084 3697225 1323675 925592 1440484 1456949 38295 
64 
 
Protein (WT and variants) Time (min) 0 0.5 1 2 5 10 30 60 120 
 2nd 6814198 4549208 4459680 3740986 2806528 2661824 2317316 1821720 561792 
 3rd 7874562 7152100 4058381 3633521 3531587 2576902 1906758 692233 71336 
 AVG 7274095 5510614 3847382 3690577 2553930 2054773 1888186 1323634 223808 
 SEM 314066 824751 427639 31200 649762 565122 253290 332799 169261 
I172N 4PBA treated 1st 11916110 8037658 8878335 5002992 5194245 4905201 4599544 2258295 2346318 
 2nd 10098580 6705504 5653332 6909912 13061300 4281056 3383384 2390460 2359680 
 3rd 13174100 10262660 6969116 7613518 8581158 6212616 4905724 3524100 502962 
 AVG 11729597 8335274 7166928 6508807 8945568 5132958 4296217 2724285 1736320 
 SEM 892711 1037589 936217 779824 2278321 569103 464896 401723 616691 
V281G 37°C 1st 1978496 2044160 1359392 1995424 301408 252544 161984 65184 57696 
 2nd 1812030 1146985 1257060 801710 802865 643440 288995 312970 246925 
 3rd 2411552 2173312 2035520 1737344 967680 1119200 728800 706432 356672 
 AVG 2067359 1788152 1550657 1511493 690651 671728 393260 361529 220431 
 SEM 178680 322744 244224 362627 200353 250582 171730 186698 87318 
V281L 37°C 1st 4423774 2817172 2683688 6274020. 4448594. 1548666 212194 208556 145656 
 2nd 2375345 1795808 1950048 3111392. 1310208 1202720 590208 380416 500960 
 3rd 2985567 2577600 1928352 1886304 2140256. 1342720 850592 482752 431104 
 4th 4957632 3207204 1953612. 2391084 3035772 1672920 770400 171936 260460 
 5th 4102138 4292366 4742362 4450218 3233534 2935234 1940052 2015406 3251926.* 
 6th 3711688 4427988 3898230 4937948 2767464 3996384 685216 768094 362862 
 AVG 3759357 3186356 3040536 2909202 2586745 1441757 841444 671193 340208 
 SEM 387785 416567 556116 784166 436097 104807 237736 282822 62780 
V281G 30°C 1st 3915795 4356846 3380949 2106195 2430246 1710540 1676142 888693 1030653 
 2nd 4028893 2400116 2115179 2601988 1253930 803048 351093 237355 42624 
 3rd 5382470 4196552 4212144 3196338 3125954 2434200 2578866 2066588 743104 
65 
 
Protein (WT and variants) Time (min) 0 0.5 1 2 5 10 30 60 120 
 AVG 4442386 3651171 3236091 2634840 2270043 1649263 1535367 1064212 605460 
 SEM 471175 627237 609659 315126 546311 471869 646943 535297 293405 
V281L 30°C 1st 1658283 1338381 1019436 1101177 861663 577632 321915 267762 101574 
 2nd 1654950 1685754 1373158 959208 929968 689146 409802 148988 104992 
 3rd 2367024 1941885 1655676 2007390 1029270 861531 688215 299310 279807 
 4th 5302044 3702744 3305736 3275676 2603844 2019996 1302984 820656 199188 
 AVG 2745575 2167191 1838502 1835863 1356186 1037076 680729 384179 171390 
 SEM 868452 526576 506097 533133 417307 332803 221624 149048 42632 
D322G 37°C 1st 5072935 6130390 4105780 3735725 3900190 2308180 5047735 1864660 1956710 
 2nd 6523560 5741172 11481160 3951252 4952124 1496124 2982024 1921680 452340 
 3rd 4076205 3546642 4650393 2502465 1483185 1153086 406560 241329 8349 
 AVG 5224233 5139401 6745778 3396481 3445166 1652463 2812106 1342556 805800 
 SEM 550374 804267 2372905 451317 1026916 342487 1342483 550860 589556 
D322G 30°C 1st 3354540 3622150 2409120 3471755 1865080 2407545 1245090 1811565 519330 
 2nd 10093030 7013356 5687422 6000124 5529608 5185138 3954318 2972854 3345634 
 3rd 3122388 1977156 1883088 1807200 1353528 608580 754956 827352 361368 
 AVG 5523319 4204221 3326543 3759693 2916072 2733754 1984788 1870590 1408777 
 SEM 2285838 1482670 1190166 1218925 1315085 1331169 994878 620056 969501 
R356Q 37°C 1st 11820890 6403572 5655312 5654448 4618332 3293424 2629872 1865700 594972 
 2nd 5696600 4830735 2540125 2767380 2356165 1904035 1261540 1067045 1617140 
 3rd 7261452 7448976 3789972 3853836 3847824 3681684 2045952 1758168 1669032 
 AVG 8259647 6227761 3995136 4091888 3607440 2959714 1979121 1563638 1293715 
 SEM 1837029 760916 905109 841881 664000 539608 396414 250229 349692 
R356W 37°C 1st 6390825 3741500 3954545 1416905 5162255 1941975 1948905 1069495 1334270 
 2nd 6706398 4851403 3618156 3273575 3108851 2810335 2849000 2016611 2203498 
66 
 
Protein (WT and variants) Time (min) 0 0.5 1 2 5 10 30 60 120 
 3rd 6135290 4627420 2877525 1645595 1270605 2239790 876435 1090565 1016785 
 AVG 6410838 4406774 3483409 2112025 3180570 2330700 1891447 1392224 1518184 
 SEM 165168 338863 318125 584515 1123995 254762 570155 312253 354702 
R356Q 30°C 1st 1732230 2351934 1675458 1293672 1607134 408462 904210 312208 311828 
 2nd 2170662 1903558 1215772 1380366 1116764 992120 1193264 705296 30974 
 3rd 3883790 3934102 3340504 2309450 1995456 1984474 1495148 1244196 1093298 
 AVG 2595561 2729865 2077245 1661163 1573118 1128352 1197541 753900 478700 
 SEM 656431 615874 645419 325108 254226 460026 170603 270137 317814 
R356W 30°C 1st 3179965 4323043 3154916 2869646 2918042 1995521 1443888 1068227 811447 
 2nd 1153116 1284552 832104 735156 722484 727324 152216 64152 25128 
 3rd 5851764 6894216 5703588 5325552 4050252 3692628 2737944 1843236 933876 
 AVG 3394948 4167270 3230203 2976785 2563593 2138491 1444683 991872 590150 
 SEM 1360635 1621242 1406780 1326216 976855 858989 746435 514994 284713 
R356Q 4PBA treated 1st 8876016 10715580 6336252 9032220 9410795 3541932 2532600 1831356 290340 
 2nd 8174232 13246740 14764250 10012680 8952480 4580784 6974820 4238568 1726308 
 3rd 5166404 4766986 4452992 6131566 3300022 2466590 3773362 1294204 751640 
 AVG 7405551 9576435 8517831 8392155 7221099 3529769 4426927 2454709 922763 
 SEM 1137755 2513284 3170172 1165193 1964998 610346 1323341 905308 423266 
R356W 4PBA treated 1st 6188256 5339664 2966292 5519412 4926060 4325940 1913364 2508480 1109376 
 2nd 12228650 8822205 10997420 10450790 13266260 6823880 3464860 2399845 1637160 
 3rd 5230320 10647600 4184034 7426986 6803118 2599472 1938319 782476 603914 
 AVG 7882409 8269823 6049249 7799063 8331813 4583097 2438848 1896934 1116817 
 SEM 2190645 1556962 2498935 1435671 2526026 1226241 513057 558111 298296 
G375S 37°C 1st 3585420 6553188 3848976 3895416 2468700 1792512 1403424 1505304 1459368 
 2nd 4730364 6422904 4547448 5086764 2278332 2806560 1983096 2895084 1193976 
67 
 
Protein (WT and variants) Time (min) 0 0.5 1 2 5 10 30 60 120 
 3rd 3210725 3854935 3739610 3807160 1985410 2579640 1809535 2359525 3289090 
 AVG 3842170 5610342 4045345 4263113 2244147 2392904 1732018 2253304 1980811 
 SEM 457080 878509 253029 412613 140557 307260 171767 404695 658610 
G375S 30°C 1st 3965472 6257556 2170224 3211812 2244780 977760 866736 834012 201708 
 2nd 2653980 2232685 2819950 1758855 1297870 955290 1214605 301805 177485 
 3rd 6211523 4486509 5503306 4698371 2965735 5123168 2085061 1162688 1831019 
 AVG 4276992 4325583 3497827 3223013 2169462 2352073 1388801 766168 736737 
 SEM 1038719 1164663 1020130 848584 482942 1385563 362324 250820 547186 
P453S 37°C 1st 7878852 5742144 4843296 4326264 4344336 3444588 1624572 1517940 1401840 
 2nd 3888444 4434722 5849054 3420128 2815676 2083180 1020000 700230 502010 
 3rd 5555838 4711516 4755682 4053072 3611956 3333326 2544934 2135370 2126326 
 AVG 5774378 4962794 5149344 3933155 3590656 2953698 1729835 1451180 1343392 
 SEM 1157103 397783 350768 268363 441415 436442 443346 415632 469809 
P453S 30°C 1st 4686272 4263029 4179372 2767970 3160614 1796091 1766158 763606 563214 
 2nd 3151512 2519663 3006583 3811703 2054499 1469788 959706 803418 316387 
 3rd 7212286 6738578 6561460 4476856 4753002 4297306 2757774 2147874 1741198 
 AVG 5016690 4507090 4582472 3685510 3322705 2521062 1827879 1238299 873600 
 SEM 1183829 1223994 1045810 497332 783195 893103 519974 454933 439612 
R483Q 37°C 1st 5373576 2601036 3861936 3604788 2076300 3765348 1480068 4140072 1202940 
 2nd 3218296 5864008 4325654 3952342 2500742 2250208 2183252 856292 947226 
 3rd 6700005 3464097 3873246 4749498 2540226 2173587 1705080 3173274 1109433 
 AVG 5097292 3976380 4020279 4102209 2372423 2729714 1789467 2723213 1086533 
 SEM 1014532 976144 152723 338839 148499 518289 207330 974289 74701 
R483W 37°C 1st 3093524 1437249 1673001 1398771 1347126 993762 316899 683892 492987 
 2nd 2886176 1815872 1516000 671872 738720 279392 205504 220256 104352 
68 
 
Protein (WT and variants) Time (min) 0 0.5 1 2 5 10 30 60 120 
 3rd 809550 477085 539210 405650 444080 232995 354690 345765 83370 
 AVG 2263083 1243402 1242737 825431 843309 502050 292364 416638 226903 
 SEM 729227 398443 354671 296793 265880 246221 44779 138452 133180 
R483Q 30°C 1st 4159365 4216520 3433850 2742120 3896770 2069655 1594740 1333675 827295 
 2nd 4643892 3487320 4096696 3091150 2077472 1620848 891648 1347516 915732 
 3rd 2196324 2653008 2319786 1463266 1411358 1716384 1081860 660972 600400 
 AVG 3666527 3452283 3283444 2432179 1744415 1802296 1189416 1114054 781142 
 SEM 748290 451687 518433 494823 333057 136495 209969 226576 93908 
R483W 30°C 1st 1118362 1037702 1120730 524438 277463 772634 294224 203648 13135 
 2nd 330400 753340 892745 548450 291235 235760 346815 378000 124565 
 3rd 9137408 7213600 6111168 3317600 1192864 2756224 920224 727584 43232 
 AVG 3528723 3001547 2708214 1463496 587187 1254873 520421 436411 60311 
 SEM 2813552 2107626 1702749 927078 302864 766507 200477 154041 33281 
R483Q 4PBA treated 1st 7559388 5592708 5056308 3437964 5292000 4193352 2051724 1058256 893844 
 2nd 5258884 2198762 2823581 4384426 3271392 2334441 2142226 3181371 589558 
 3rd 7664090 5087705 6869765 4915435 5558665 4136440 3633315 2441845 2103745 
 AVG 6827454 4293058 4916551 4245942 4707352 3554744 2609088 2227157 1195716 
 SEM 784867 1057247 1170121 432093 722095 610373 512779 622220 462434 
R483W 4PBA treated 1st 3525552 2054700 3482748 1487844 3628116 1095732 1451520 1058256 320868 
 2nd 6017935 4027835 3493140 3856860 2787855 2695000 1325975 1756090 1358035 
 3rd 4986648 3189024 2854872 2946492 2444364 1231200 1101168 1000332 443304 
 AVG 4843378 3090520 3276920 2763732 2953445 1673977 1292888 1271559 707402 
 SEM 723046 571720 211045 689954 351607 512007 102482 242842 327231 





Table 4 Comparison of half‐lives  from variant protein pairs which have  the  same 
mutation site   






37°C 0.008 <0.001 0.027 <0.001 
30°C 0.020 <0.001 <0.001 <0.001 
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